Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic

Journal of Infectious Diseases

Volumn 204, Issue 1, 2011, Pages 19-26

  Greenhouse, Bryan ^a   Ho, Benjamin ^c   Hubbard, Alan ^b   Njama Meya, Denise ^d   Narum, David L ^e   Lanar, David E ^f   Dutta, Sheetij ^f   Rosenthal, Philip J ^a   Dorsey, Grant ^a   John, Chandy C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; IMMUNOGLOBULIN G; LIVER STAGE ANTIGEN 1; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHILD; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; EXPOSURE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA; PARASITEMIA; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SYMPTOMATOLOGY; UGANDA;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFANT; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; RISK FACTORS; UGANDA;

EID: 79957928865     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir223     Document Type: Article

References (50)

1. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
2. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45:297-308.
3. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 2010; 7:e1000218.
4. Bejon P, Warimwe G, Mackintosh CL, et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009; 77:1917-23.
5. Belizario VY, Saul A, Bustos MD, et al. Field epidemiological studies on malaria in a low endemic area in the Philippines. Acta Trop 1997; 63:241-56. (Pubitemid 27141752)
6. Smith DL, Dushoff J, Snow RW, Hay SI. The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature 2005; 438:492-5. (Pubitemid 41742019)
7. Kreuels B, Kobbe R, Adjei S, et al. Spatial variation of malaria incidence in young children from a geographically homogeneous area with high endemicity. J Infect Dis 2008; 197:85-93. (Pubitemid 351263471)
8. Clark TD, Greenhouse B, Njama-Meya D, et al. Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J infect dis 2008; 198:393-400.
9. Brooker S, Clarke S, Njagi JK, et al. Spatial clustering of malaria and associated risk factors during an epidemic in a highland area of western Kenya. Trop Med Int Health 2004; 9:757-66. (Pubitemid 38962002)
10. Ernst KC, Adoka SO, Kowuor DO, Wilson ML, John CC. Malaria hotspot areas in a highland Kenya site are consistent in epidemic and non-epidemic years and are associated with ecological factors. Malar J 2006; 5:78.
11. Oesterholt MJ, Bousema JT, Mwerinde OK, et al. Spatial and temporal variation in malaria transmission in a low endemicity area in northern Tanzania. Malar J 2006; 5:98.
12. Wilson S, Booth M, Jones FM, et al. Age-adjusted Plasmodium falciparum antibody levels in school-aged children are a stable marker of microgeographical variations in exposure to Plasmodium infection. BMC Infect Dis 2007; 7:67.
13. Bejon P, Williams TN, Liljander A, et al. Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med 2010; 7:e1000304.
14. Bousema T, Drakeley C, Gesase S, et al. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 2010; 201:1764-4.
15. Davis JC, Clark TD, Kemble SK, et al. Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment. Malar J 2006; 5:18.
16. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210-9.
17. Clark TD, Njama-Meya D, Nzarubara B, et al. Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One 2010; 5:e11759.
18. John CC, Moormann AM, Pregibon DC, et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 2005; 73:222-8. (Pubitemid 41278777)
19. Dutta S, Lalitha PV, Ware LA, et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 2002; 70:3101-0.
20. Shimp RL Jr., Martin LB, Zhang Y, et al. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. Protein Expr Purif 2006; 50:58-67. (Pubitemid 44755034)
21. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun 2003; 71:6766-4.
22. Tsai CW, Duggan PF, Jin AJ, et al. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Mol Biochem Parasitol 2009; 164:45-56.
23. John CC, Ouma JH, Sumba PO, Hollingdale MR, Kazura JW, King CL. Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission. Am J Trop Med Hyg 2002; 66:372-8. (Pubitemid 34810489)
24. Greenhouse B, Slater M, Njama-Meya D, et al. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis 2009; 199:758-65.
25. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
26. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3:319-36.
27. van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol 2007; 6:Article25.
28. Breiman L. Random forests. Machine Learning 2001; 45:5-32.
29. Hastie T, Tibshirani R. Generalized additive models, 1st ed. London, New York: Chapman and Hall, 1990. Monographs on statistics and applied probability 43.
30. Ripley BD. Pattern recognition and neural networks. Cambridge, New York: Cambridge University Press, 1996.
31. Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010; 33:1-22.
32. Polley SD, Mwangi T, Kocken CH, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004; 23:718-28. (Pubitemid 39473204)
33. Polley SD, Tetteh KK, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J infectious diseases 2007; 195:279-87. (Pubitemid 46080060)
34. Osier FH, Polley SD, Mwangi T, Lowe B, Conway DJ, Marsh K. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol 2007; 29:387-94. (Pubitemid 47083924)
35. Dodoo D, Aikins A, Kusi KA, et al. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J 2008; 7:142.
36. Nebie I, Diarra A, Ouedraogo A, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 2008; 76:759-66. (Pubitemid 351251748)
37. Meraldi V, Nebie I, Tiono AB, et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004; 26:265-72.
38. Gray JC, Corran PH, Mangia E, et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin chem 2007; 53:1244-53. (Pubitemid 47020980)
39. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009; 77:1165-74.
40. Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76:2240-8. (Pubitemid 351656161)
41. Zhou Z, Xiao L, Branch OH, Kariuki S, Nahlen BL, Lal AA. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Am J Trop Med Hyg 2002; 66:7-12. (Pubitemid 34733146)
42. Wongsrichanalai C, Webster HK, Permpanich B, Chuanak N, Ketrangsri S. Naturally acquired circumsporozoite antibodies and their role in protection in endemic falciparum and vivax malaria. Am J Trop Med Hyg 1991; 44:201-4.
43. Kitua AY, Urassa H, Wechsler M, et al. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol 1999; 21:307-17. (Pubitemid 29257759)
44. John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003; 71:4320-5. (Pubitemid 36919895)
45. John CC, Tande AJ, Moormann AM, et al. Antibodies to preerythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 2008; 197:519-26. (Pubitemid 351321528)
46. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasioninhibiting antibodies. J Exp Med 1990; 172:379-82. (Pubitemid 20217284)
47. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
48. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32.
49. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64. (Pubitemid 34297774)
50. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006; 28:51-60.